Impact of morbid obesity on treatment outcome in a clinical trial of major depressive disorder

Morbid obesity often reflects underlying co-morbid conditions and life style differences that may affect the antidepressant treatment response. The findings from this post-hoc analysis suggest that morbid obesity is a moderating factor that may confound the interpretation of clinical trial results by blunting the drug response and/or generating a higher placebo response.